{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:53:23Z","timestamp":1773258803214,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018747","name":"SkylineDx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018747","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejso.2023.107249","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T11:26:15Z","timestamp":1698319575000},"page":"107249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-6966","authenticated-orcid":false,"given":"Robert C.","family":"Stassen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-2171","authenticated-orcid":false,"given":"Evalyn E.A.P.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-5780","authenticated-orcid":false,"given":"Antien L.","family":"Mooyaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Brecht","family":"Francken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-1323","authenticated-orcid":false,"given":"Jos","family":"van der Hage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen J.B.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-6002","authenticated-orcid":false,"given":"Dirk J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2023.107249_bib1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","article-title":"Technical details of intraoperative lymphatic mapping for early stage melanoma","volume":"127","author":"Morton","year":"1992","journal-title":"Arch Surg"},{"key":"10.1016\/j.ejso.2023.107249_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.annonc.2020.11.015","article-title":"Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor","volume":"32","author":"El Sharouni","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib3","series-title":"Melanoma","author":"Workgroup","year":"2019"},{"key":"10.1016\/j.ejso.2023.107249_bib4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2023.107249_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ejso.2023.107249_bib6","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American joint committee on cancer (AJCC) and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib7","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa1310460","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2023.107249_bib10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1200\/JCO.2003.07.170","article-title":"Clinical outcome of stage I\/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results","volume":"21","author":"Vuylsteke","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib11","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1999.17.3.976","article-title":"Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients","volume":"17","author":"Gershenwald","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib12","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejso.2016.06.407","article-title":"Complications of sentinel lymph node biopsy for melanoma \u2013 a systematic review of the literature","volume":"43","author":"Moody","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archsurg.140.1.85","article-title":"Identifying risk factors for complications following sentinel lymph node biopsy for melanoma","volume":"140","author":"Roaten","year":"2005","journal-title":"Arch Surg"},{"key":"10.1016\/j.ejso.2023.107249_bib14","doi-asserted-by":"crossref","first-page":"v540","DOI":"10.1093\/annonc\/mdz255.014","article-title":"Validation of a clinicopathological and gene expression profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma","volume":"30","author":"Mulder","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib15","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jamadermatol.2020.1729","article-title":"Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit","volume":"156","author":"Grossman","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejso.2023.107249_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-018-0690-3","article-title":"Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients","volume":"13","author":"Cook","year":"2018","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.ejso.2023.107249_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/PO.19.00206","article-title":"Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma","volume":"4","author":"Bellomo","year":"2020","journal-title":"Jco Precision Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib18","doi-asserted-by":"crossref","first-page":"MMT32","DOI":"10.2217\/mmt-2019-0016","article-title":"Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice","volume":"6","author":"Grossman","year":"2019","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.ejso.2023.107249_bib19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejso.2021.11.010","article-title":"Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary","volume":"48","author":"Johansson","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib20","series-title":"Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a US cohort study","author":"Yousaf","year":"2021"},{"key":"10.1016\/j.ejso.2023.107249_bib21","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1111\/ijd.14987","article-title":"Primary cutaneous melanoma risk stratification using a clinicopathologic and gene expression model: a pilot study","volume":"59","author":"Arias-Mejias","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ejso.2023.107249_bib22","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/SLA.0b013e3181b07ffd","article-title":"Sentinel node status prediction by four statistical models: results from a large Bi-institutional series (n\u00a0= 1132)","volume":"250","author":"Mocellin","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2023.107249_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/02841860701785533","article-title":"Sentinel node biopsy in malignant melanoma: Swedish experiences 1997\u20132005","volume":"47","author":"Mattsson","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1245\/s10434-015-4766-y","article-title":"Identification of patients with intermediate thickness melanoma at low risk for sentinel lymph node positivity","volume":"23","author":"Bartlett","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2023.107249_bib25","series-title":"MElanoma research lymph node prediction implementation National_001 (MERLIN_001)","year":"2021"},{"key":"10.1016\/j.ejso.2023.107249_bib26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2016.08.014","article-title":"Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival","volume":"67","author":"Oude Ophuis","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798323008879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798323008879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:50:00Z","timestamp":1760061000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798323008879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0748798323008879"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2023.107249","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2023.107249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107249"}}